Crenezumab did not show a statistically significant clinical benefit in either of its co-primary endpoints assessing the rate of change in cognitive abilities or episodic memory function: Statement.
from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/X4Rfr9t
Home »
Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com
» Roche suffers setback with Alzheimer's treatment
https://ift.tt/oC8E9zX
No comments:
Post a Comment